Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) Releases Earnings Results, Misses Expectations By $0.08 EPS

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) released its quarterly earnings data on Thursday. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.08), FiscalAI reports. Senseonics Holdings, Inc. Common Stock had a negative return on equity of 129.97% and a negative net margin of 213.87%.The business had revenue of $14.48 million for the quarter.

Here are the key takeaways from Senseonics Holdings, Inc. Common Stock’s conference call:

• Q2 revenue rose approximately 120% year over year to $14.5 million, led by U.S. revenue growth of more than 150% and continued adoption of Eversense 365. Management raised full-year 2026 revenue guidance to $62 million-$66 million, implying roughly 80% annual growth.
• Gross margin increased to 59%, the company’s strongest organic performance, supported by manufacturing improvements and a favorable reimbursement mix. Full-year gross margin guidance was raised to 58%-61% from 55%-58%.
• The Eon Care network expanded to more than 90 providers and performed a record number of insertions, accounting for approximately 40% of U.S. insertions in Q2. Management expects Eon to exceed 100 providers and represent more than half of U.S. insertions by year-end.
• The European commercial transition from Ascensia was completed, but delayed tender updates and inventory adjustments pushed some revenue into the third and fourth quarters. Management expects no full-year impact and continues to forecast Europe at approximately 20% of total 2026 revenue.
• Despite stronger revenue and margins, the net loss widened to $36.7 million from $14.5 million a year earlier as selling, general and administrative expenses rose sharply following the commercial transition and investments in Gemini and Freedom. The company expects 2026 operating expenses of $150 million-$160 million and cash utilization of $110 million-$120 million.

Senseonics Holdings, Inc. Common Stock Stock Down 0.6%

Shares of SENS traded down $0.03 during midday trading on Thursday, reaching $5.15. The stock had a trading volume of 545,456 shares, compared to its average volume of 457,173. Senseonics Holdings, Inc. Common Stock has a 52 week low of $4.79 and a 52 week high of $11.58. The company has a debt-to-equity ratio of 1.05, a quick ratio of 3.19 and a current ratio of 3.51. The firm has a 50 day moving average of $5.85.

Analysts Set New Price Targets

Several equities analysts have recently commented on SENS shares. Stifel Nicolaus lowered their target price on Senseonics Holdings, Inc. Common Stock from $9.00 to $8.00 and set a “hold” rating for the company in a report on Monday, May 11th. Weiss Ratings raised Senseonics Holdings, Inc. Common Stock from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 28th. HC Wainwright reduced their price objective on Senseonics Holdings, Inc. Common Stock from $18.50 to $14.00 and set a “buy” rating for the company in a research report on Tuesday, May 12th. Finally, Mizuho lowered their price objective on Senseonics Holdings, Inc. Common Stock from $20.00 to $18.00 and set an “outperform” rating for the company in a research note on Wednesday, July 15th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $17.20.

Insider Buying and Selling at Senseonics Holdings, Inc. Common Stock

In other news, Director Douglas A. Roeder bought 22,686 shares of the firm’s stock in a transaction that occurred on Tuesday, May 12th. The stock was acquired at an average price of $5.56 per share, with a total value of $126,134.16. Following the completion of the purchase, the director directly owned 144,635 shares of the company’s stock, valued at $804,170.60. This represents a 18.60% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 4.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Senseonics Holdings, Inc. Common Stock

Institutional investors and hedge funds have recently bought and sold shares of the business. Masters Capital Management LLC increased its stake in Senseonics Holdings, Inc. Common Stock by 100.0% in the 1st quarter. Masters Capital Management LLC now owns 500,000 shares of the company’s stock worth $3,330,000 after purchasing an additional 250,002 shares in the last quarter. State of Wyoming purchased a new stake in Senseonics Holdings, Inc. Common Stock during the second quarter valued at about $67,000. Bank of America Corp DE boosted its holdings in shares of Senseonics Holdings, Inc. Common Stock by 126.8% in the first quarter. Bank of America Corp DE now owns 56,964 shares of the company’s stock worth $379,000 after buying an additional 31,849 shares during the period. Cetera Investment Advisers acquired a new position in shares of Senseonics Holdings, Inc. Common Stock in the first quarter worth about $85,000. Finally, Captrust Financial Advisors purchased a new position in shares of Senseonics Holdings, Inc. Common Stock in the fourth quarter worth approximately $77,000. 12.36% of the stock is owned by institutional investors and hedge funds.

About Senseonics Holdings, Inc. Common Stock

Senseonics Holdings, Inc develops and commercializes long-term implantable continuous glucose monitoring (CGM) systems for people with diabetes. The company’s primary product family is the Eversense system, which combines a small subcutaneously implanted sensor, a removable external transmitter, and companion smartphone applications to provide continuous glucose readings and alerts. Senseonics positions its technology as an alternative to wearable patch-style CGMs by offering multi-month sensor longevity and on-body vibration alerts delivered through the transmitter.

Senseonics supports clinical and commercial activities that include research and development, regulatory engagement, manufacturing and distribution, and training for healthcare providers who perform sensor insertion and removal.